<Disease><Name>PHENYLKETONURIA (PKU)</Name><Synonym>HYPERPHENYLALANINEMIA, MILD, INCLUDED; HPA, INCLUDED</Synonym><OMIM><Number>261600</Number><URL>http://omim.org/entry/261600</URL></OMIM><Orphanet><Number>716</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=716</URL></Orphanet><Protein><Number>phenylalanine hydroxylase (PAH)</Number><URL>http://www.uniprot.org/uniprot/P00439</URL></Protein><ExPASy><Number>1.14.16.1</Number><URL>http://enzyme.expasy.org/EC/1.14.16.1</URL></ExPASy><Gene>12q23.2Detail information to gene locus by the National Center for Biotechnology Information NCBI:

Phenylalanine hydroxylase
</Gene><ICD>E70.1</ICD><Summary>1:5000 - 1:12500;autosomal recessive ;mutations in the PAH gene;phenylalanine concentrations in plasma: ;- classical PKU: &gt; 20 mg/dl ;- mild PKU: 10-20 mg/dl ;- Hyperphenylalaninemia (HPA): &lt; 10 mg/dl</Summary><Symptoms><symtomp><id>2074</id><symptom>Amino acids, plasma</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1956</id><symptom>behavior, autism or autistic-like / behaviour, autism or autistic-like</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1955</id><symptom>behavior, hyperactive, restless / behaviour, hyperactive, restless</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3191</id><symptom>blue eyes</symptom><category>EYES</category></symtomp><symtomp><id>4068</id><symptom>decreased body height</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2160</id><symptom>EEG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>3630</id><symptom>embryopathy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3190</id><symptom>fair hair</symptom><category>SKIN</category></symtomp><symtomp><id>1896</id><symptom>hypertonia, spasticity</symptom><category>MUSCLES</category></symtomp><symtomp><id>3225</id><symptom>hypopigmentation</symptom><category>SKIN</category></symtomp><symtomp><id>3826</id><symptom>intellectual disability/intellectual developmental disorder</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1951</id><symptom>irritability</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3843</id><symptom>leukodystrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3863</id><symptom>low birthweight (small for gestational age)</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1886</id><symptom>microcephaly (&lt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>1706</id><symptom>mousy body odor</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2426</id><symptom>MRI, brain, white matter abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2504</id><symptom>onset, neonatal / neonatal</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2089</id><symptom>Organic acids, urine</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2268</id><symptom>pigmentation, skin and sclera</symptom><category>SKIN</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>3343</id><symptom>skin rash, eczematous or seborrhoic / skin rash</symptom><category>SKIN</category></symtomp><symtomp><id>1700</id><symptom>small for gestational age (SGA), intrauterine growth retardation (IUGR)</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2329</id><symptom>unusual odor / odour</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1980</id><symptom>vomiting</symptom><category>GASTROINTESTINAL SYSTEM | GENERAL TOPICS</category></symtomp></Symptoms><Metabolites><metabolite><id>1584</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>1.50</min><max>3.90</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1624</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value>increased</value><min>1.80</min><max>12.70</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1652</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>3.50</min><max>11.20</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1656</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>4.10</min><max>23.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1669</id><name>2-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.90</min><max>4.50</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1674</id><name>Phenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>3.25</min><max>5.07</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1778</id><name>N-Acetylphenylalanine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>87.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1781</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>120.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1790</id><name>2-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>10.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1791</id><name>3-Phenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>85.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1796</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>470.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1800</id><name>Phenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>470.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1801</id><name>Phenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>85.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1837</id><name>Neopterin</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>17.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1846</id><name>D-Mannitol</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>430.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>1874</id><name>D-Mannitol</name><specimen>urine</specimen><value>normal/inc</value><min>5.20</min><max>85.10</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1961</id><name>Phenylalanine</name><specimen>blood</specimen><value>normal/inc</value><min>0.00</min><max>120.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1962</id><name>Phenylalanine</name><specimen>plasma</specimen><value>increased</value><min>34.00</min><max>86.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>1969</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>34.00</min><max>112.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1970</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>19.00</min><max>119.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1971</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>increased</value><min>35.00</min><max>107.00</max><unit>&#956;mol/l</unit><age>Adolescence</age><method>HPLC</method><comment /></metabolite><metabolite><id>2089</id><name>Biopterin</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>2090</id><name>Biopterin</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>2.70</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>65</id><name>2-Hydroxyphenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>675</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>3.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>infancy</age><method /><comment /></metabolite><metabolite><id>677</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>9.00</max><unit>mmol/mol creatinine</unit><age>childhood 6-12y</age><method /><comment /></metabolite><metabolite><id>678</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>7.00</max><unit>mmol/mol creatinine</unit><age>adolescence</age><method /><comment /></metabolite><metabolite><id>674</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.10</min><max>11.50</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>676</id><name>4-Hydroxyphenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.30</min><max>5.80</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1387</id><name>5-Hydroxyindolacetic acid (5-HIAA)</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>12.00</max><unit>mmol/mol creatinine</unit><age>childhood 4-6y</age><method /><comment /></metabolite><metabolite><id>910</id><name>5-Hydroxyindolacetic acid (5-HIAA)</name><specimen>cerebrospinal fluid</specimen><value>normal/dec</value><min>120.00</min><max>500.00</max><unit>nmol/l</unit><age /><method /><comment /></metabolite><metabolite><id>931</id><name>5-Hydroxyindolacetic acid (5-HIAA)</name><specimen>cerebrospinal fluid</specimen><value>normal/dec</value><min>105.00</min><max>299.00</max><unit>nmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1001</id><name>5-Hydroxyindolacetic acid (5-HIAA)</name><specimen>urine</specimen><value>normal/dec</value><min>    </min><max>11.50</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1388</id><name>5-Hydroxyindolacetic acid (5-HIAA)</name><specimen>urine</specimen><value>normal/dec</value><min>0.20</min><max>8.70</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>424</id><name>Biopterin</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>425</id><name>Biopterin</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>3.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>426</id><name>Biopterin</name><specimen>urine</specimen><value>increased</value><min>0.50</min><max>2.70</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method /><comment /></metabolite><metabolite><id>934</id><name>Biopterin</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>10.00</min><max>50.00</max><unit>nmol/l</unit><age /><method /><comment /></metabolite><metabolite><id>1201</id><name>Ferric chloride reaction</name><specimen>urine</specimen><value /><min>    </min><max>    </max><unit>negative</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>684</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>3.00</min><max>20.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>685</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>2.00</min><max>19.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>686</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>6.00</min><max>42.00</max><unit>mmol/mol creatinine</unit><age>childhood</age><method /><comment /></metabolite><metabolite><id>687</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>1.00</min><max>14.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method /><comment /></metabolite><metabolite><id>688</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>1.00</min><max>5.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method /><comment /></metabolite><metabolite><id>2022</id><name>Homovanillic acid (HVA)</name><specimen>urine</specimen><value /><min>0.00</min><max>0.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>Bruker 2018</comment></metabolite><metabolite><id>911</id><name>Homovanillic acid (HVA)</name><specimen>cerebrospinal fluid</specimen><value>normal/dec</value><min>100.00</min><max>900.00</max><unit>nmol/l</unit><age>1m-2years</age><method /><comment /></metabolite><metabolite><id>932</id><name>Homovanillic acid (HVA)</name><specimen>cerebrospinal fluid</specimen><value>normal/dec</value><min>211.00</min><max>871.00</max><unit>nmol/l</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1919</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>2.00</min><max>19.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1924</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>2.00</min><max>23.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1763</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>0.00</min><max>43.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment>?</comment></metabolite><metabolite><id>422</id><name>Neopterin</name><specimen>urine</specimen><value>increased</value><min>1.10</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method /><comment /></metabolite><metabolite><id>1054</id><name>Neopterin</name><specimen>urine</specimen><value>increased</value><min>1.10</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method /><comment /></metabolite><metabolite><id>423</id><name>Neopterin</name><specimen>urine</specimen><value>increased</value><min>1.10</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method /><comment /></metabolite><metabolite><id>427</id><name>Neopterin</name><specimen>urine</specimen><value>increased</value><min>0.20</min><max>1.70</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method /><comment /></metabolite><metabolite><id>935</id><name>Neopterin</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>9.00</min><max>20.00</max><unit>nmol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>1055</id><name>Neopterin</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>9.00</min><max>40.00</max><unit>nmol/l</unit><age>1m-2years</age><method /><comment /></metabolite><metabolite><id>361</id><name>Phenylacetic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>0.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1548</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>5.00</min><max>20.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>156</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>4.00</min><max>32.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>871</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>6.00</min><max>31.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1513</id><name>Phenylalanine</name><specimen>urine</specimen><value>increased</value><min>7.00</min><max>28.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>52</id><name>Phenylalanine</name><specimen>plasma</specimen><value>increased</value><min>21.00</min><max>137.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>930</id><name>Phenylalanine</name><specimen>cerebrospinal fluid</specimen><value>increased</value><min>0.00</min><max>20.00</max><unit>&#956;mol/l</unit><age>infant</age><method /><comment /></metabolite><metabolite><id>1057</id><name>Phenylalanine</name><specimen>plasma</specimen><value>increased</value><min>35.00</min><max>85.00</max><unit>&#956;mol/l</unit><age>Adulthood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1294</id><name>Phenylalanine</name><specimen>plasma</specimen><value>increased</value><min>26.00</min><max>85.00</max><unit>&#956;mol/l</unit><age>Infancy</age><method>HPLC</method><comment /></metabolite><metabolite><id>1295</id><name>Phenylalanine</name><specimen>plasma</specimen><value>increased</value><min>26.00</min><max>98.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite><metabolite><id>1306</id><name>Phenylalanine/Tyrosine</name><specimen>serum</specimen><value>increased</value><min>0.20</min><max>1.21</max><unit>ratio</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>64</id><name>3-Phenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>2.00</max><unit>mmol/mol creatinine</unit><age>child</age><method /><comment /></metabolite><metabolite><id>1357</id><name>3-Phenyllactic acid</name><specimen>urine</specimen><value>increased</value><min>    </min><max>    </max><unit>not detectable</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>63</id><name>Phenylpyruvic acid</name><specimen>urine</specimen><value>increased</value><min>0.00</min><max>4.00</max><unit>mmol/mol creatinine</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>155</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>55.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>870</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>9.00</min><max>48.00</max><unit>mmol/mol creatinine</unit><age>Childhood</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1553</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>6.00</min><max>26.00</max><unit>mmol/mol creatinine</unit><age>Adolescence</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>1517</id><name>L-Tyrosine</name><specimen>urine</specimen><value>decreased</value><min>11.00</min><max>54.00</max><unit>mmol/mol creatinine</unit><age>Infancy</age><method>HPLC</method><comment>fasted</comment></metabolite><metabolite><id>53</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>decreased</value><min>38.00</min><max>147.00</max><unit>&#956;mol/l</unit><age>Neonatal</age><method>HPLC</method><comment /></metabolite><metabolite><id>1298</id><name>L-Tyrosine</name><specimen>blood</specimen><value>decreased</value><min>29.06</min><max>178.41</max><unit>&#181;mol/l</unit><age>newborn</age><method /><comment /></metabolite><metabolite><id>1299</id><name>L-Tyrosine</name><specimen>plasma</specimen><value>decreased</value><min>14.00</min><max>115.00</max><unit>&#956;mol/l</unit><age>Childhood</age><method>HPLC</method><comment /></metabolite></Metabolites><Literatures><literature><id>7302</id><title>BioPKU</title><author>WEBSITE MANAGER: Nenad Blau</author><journal /><year>9999</year><book /><volume>0</volume><number>0</number><pages /><co_aut /></literature><literature><id>6946</id><title>Tetrahydrobiopterin treatment in phenylketonuria: A repurposing approach</title><author>Evers RAF,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>43</volume><number>2</number><pages>189-199</pages><co_aut>van Vliet D, van Spronsen FJ</co_aut></literature><literature><id>7308</id><title>Case-control study about the acceptance of Pegvaliase in Phenylketonuria</title><author>Kr&#228;mer J</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>22</volume><number>0</number><pages>100557</pages><co_aut /></literature><literature><id>7309</id><title>Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: A case report</title><author>Rohr F,</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>22</volume><number>0</number><pages>100555</pages><co_aut>et al.</co_aut></literature><literature><id>7330</id><title>Management of three preterm infants with phenylketonuria</title><author>Weiss K,</author><journal>Nutrition</journal><year>2020</year><book /><volume>71</volume><number>0</number><pages>110619</pages><co_aut>et al.</co_aut></literature><literature><id>7388</id><title>Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review</title><author>Pugliese M,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>12</pages><co_aut>et al.</co_aut></literature><literature><id>7694</id><title>Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to he</title><author>Cannet C,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>61</pages><co_aut>et al.</co_aut></literature><literature><id>7695</id><title>Emotional health in early-treated adults with phenylketonuria (PKU): Relationship with cognitive abilities and blood phenylalan</title><author>Palermo L,</author><journal>J Clin Exp Neuropsychol</journal><year>2020</year><book /><volume>42</volume><number>2</number><pages>142-159</pages><co_aut>et al.</co_aut></literature><literature><id>7696</id><title>Phenylketonuria, co-morbidity, and ageing: A review.</title><author>Vardy ERLC,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>43</volume><number>2</number><pages>167-178</pages><co_aut>et al.</co_aut></literature><literature><id>7697</id><title>The first European guidelines on phenylketonuria: Usefulness and implications for BH4 responsiveness testing</title><author>Evers RAF,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>43</volume><number>2</number><pages>244-250</pages><co_aut>et al.</co_aut></literature><literature><id>7698</id><title>Performance of laboratory tests used to measure blood phenylalanine for the monitoring of patients with phenylketonuria</title><author>Moat SJ,</author><journal>J Inherit Metab Dis</journal><year>2020</year><book /><volume>43</volume><number>2</number><pages>179-188</pages><co_aut>et al.</co_aut></literature><literature><id>7699</id><title>Predictability and inconsistencies of cognitive outcome in patients with phenylketonuria and personalised therapy: the challeng</title><author>Leuzzi V,</author><journal>J Med Genet</journal><year>2020</year><book /><volume>57</volume><number>3</number><pages>145-150</pages><co_aut>et al.</co_aut></literature><literature><id>7927</id><title>The PKU &amp; ME study: A qualitative exploration, through co-creative sessions, of attitudes and experience of the disease among adults with phenylketonuria in Italy</title><author>Borghi L,</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>23</volume><number>0</number><pages>100585</pages><co_aut>et al.</co_aut></literature><literature><id>7929</id><title>Executive functioning, adaptive skills, emotional and behavioral profile: A comparison between autism spectrum disorder and phenylketonuria</title><author>Trimarco B,</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>23</volume><number>0</number><pages>100577</pages><co_aut>et al.</co_aut></literature><literature><id>7962</id><title>Sustaining benefits of nutritional therapy in young adults with phenylketonuria - A 2&#8239;year prospective study</title><author>Kr&#228;mer J</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>22</volume><number>0</number><pages>100573</pages><co_aut /></literature><literature><id>7974</id><title>Oral health status of children with phenylketonuria</title><author>Ballikaya E,</author><journal>J Pediatr Endocrinol Metab. 2020 Mar 26;33(3):361-365</journal><year>2020</year><book /><volume>33</volume><number>3</number><pages>361-365</pages><co_aut>et al.</co_aut></literature><literature><id>8158</id><title>Similarities and differences in key diagnosis, treatment, and management approaches for PAH deficiency in the United States and</title><author>Lowe TB,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>266</pages><co_aut>DeLuca J, Arnold GL.</co_aut></literature><literature><id>8239</id><title>Phenylalanine effects on brain function in adult phenylketonuria</title><author>Pilotto A,</author><journal>Neurology</journal><year>2020</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6373</id><title>Development of national consensus statements on food labelling interpretation and protein allocation in a low phenylalanine die</title><author>British Inherited Metabolic Diseases Group (BIMDG) Dietitian</author><journal>Orphanet J Rare Dis</journal><year>2019</year><book /><volume>14</volume><number>1</number><pages>2</pages><co_aut /></literature><literature><id>6402</id><title>A comprehensive multiplex PCR based exome-sequencing assay for rapid bloodspot confirmation of inborn errors of metabolism</title><author>Wang W,</author><journal>BMC Med Genet</journal><year>2019</year><book /><volume>20</volume><number>1</number><pages>3</pages><co_aut>et al.</co_aut></literature><literature><id>6403</id><title>The neurological and psychological phenotype of adult patients with early-treated phenylketonuria: a systematic review.</title><author>Burlina AP,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6421</id><title>Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria</title><author>Pilotto A,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages>1-9</pages><co_aut>et al.</co_aut></literature><literature><id>6650</id><title>Allelic phenotype values: a model for genotype-based phenotype prediction in phenylketonuria</title><author>Garbade SF,</author><journal>Genet Med</journal><year>2019</year><book /><volume>21</volume><number>3</number><pages>580-590</pages><co_aut>et al.</co_aut></literature><literature><id>6986</id><title>Screening and mutation analysis of hyperphenylalaninemia in newborns from Xiamen, China</title><author>Wang X,</author><journal>Clin Chim Acta</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7192</id><title>The first European guidelines on phenylketonuria: its usefulness and implications for BH4 responsiveness testing</title><author>Evers RAF,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7197</id><title>Metabolomics for improved treatment monitoring of phenylketonuria: urinary biomarkers for non-invasive assessment of dietary ad</title><author>Wild J,</author><journal>Analyst</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7198</id><title>Metabolomics analysis reveals perturbations of cerebrocortical metabolic pathways in the Pahenu2 mouse model of phenylketonuria</title><author>Lu LH,</author><journal>CNS Neurosci Ther</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7199</id><title>Assessment of the Phenylketonuria (PKU)-Associated Mutation p.R155H Biochemical Manifestations by Mass Spectrometry-Based Blood Metabolite Profiling</title><author>Baturina OA,</author><journal>Acta Naturae</journal><year>2019</year><book /><volume>11</volume><number>2</number><pages>42-46</pages><co_aut>et al.</co_aut></literature><literature><id>7233</id><title>Phenylketonuria, Co-morbidity and Ageing: a review</title><author>Vardy ERLC,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>7264</id><title>International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuri</title><author>Muntau AC,</author><journal>Mol Genet Metab</journal><year>2019</year><book /><volume>127</volume><number>1</number><pages>1-11</pages><co_aut>et al.</co_aut></literature><literature><id>7303</id><title>Biomarkers of Micronutrients in Regular Follow-Up for Tyrosinemia Type 1 and Phenylketonuria Patients</title><author>van Vliet K,</author><journal>Nutrients</journal><year>2019</year><book /><volume>11</volume><number>9</number><pages>E2011</pages><co_aut>et al.</co_aut></literature><literature><id>7310</id><title>Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain</title><author>Berguig GY,</author><journal>Mol Genet Metab</journal><year>2019</year><book /><volume>128</volume><number>4</number><pages>422-430</pages><co_aut>et al.</co_aut></literature><literature><id>7311</id><title>A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients preferences</title><author>SriBhashyam S,</author><journal>Mol Genet Metab Rep</journal><year>2019</year><book /><volume>21</volume><number>0</number><pages>100507</pages><co_aut>et al.</co_aut></literature><literature><id>7312</id><title>Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria</title><author>Longo N,</author><journal>Genet Med</journal><year>2019</year><book /><volume>21</volume><number>8</number><pages>1851-1867</pages><co_aut>et al.</co_aut></literature><literature><id>7313</id><title>A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria</title><author>Hydery T,</author><journal>Drug Target Insights</journal><year>2019</year><book /><volume>13</volume><number>0</number><pages /><co_aut>Coppenrath VA</co_aut></literature><literature><id>7314</id><title>AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria</title><author>Richards DY,</author><journal>Mol Ther Methods Clin Dev</journal><year>2019</year><book /><volume>1</volume><number>0</number><pages>234-245</pages><co_aut>et al.</co_aut></literature><literature><id>7315</id><title>State-of-the-Art 2019 on Gene Therapy for Phenylketonuria</title><author>Grisch-Chan HM,</author><journal>Hum Gene Ther</journal><year>2019</year><book /><volume>30</volume><number>10</number><pages>1274-1283</pages><co_aut>et al.</co_aut></literature><literature><id>5713</id><title>Is Propofol Safe in Patients With Phenylketonuria?</title><author>Rayadurg V,</author><journal>J Neurosurg Anesthesiol</journal><year>2018</year><book /><volume>30</volume><number>1</number><pages>85-86</pages><co_aut>Uttarwar A, Surve R</co_aut></literature><literature><id>6367</id><title>Allelic phenotype values: a model for genotype-based phenotype prediction in phenylketonuria</title><author>Garbade SF,</author><journal>Genet Med</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6368</id><title>Can untreated PKU patients escape from intellectual disability? A systematic review</title><author>van Vliet D,</author><journal>Orphanet J Rare Dis</journal><year>2018</year><book /><volume>13</volume><number>1</number><pages>149</pages><co_aut>et al.</co_aut></literature><literature><id>6374</id><title>Neurocognitive functioning in adults with phenylketonuria: Report of a 10-year follow-up</title><author>Feldmann R,</author><journal>Mol Genet Metab</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>6375</id><title>Phenylketonuria</title><author>Stone WL,</author><journal>StatPearls [Internet]</journal><year>2018</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Los E</co_aut></literature><literature><id>6378</id><title>Transient phenylketonuria in premature infants</title><author>Salamanca-Zarzuela B,</author><journal>Nutrition</journal><year>2018</year><book /><volume>59</volume><number>0</number><pages>180-181</pages><co_aut>Lopez MEI, Mart&#237;n CA</co_aut></literature><literature><id>6379</id><title>Reproductive experience of women living with phenylketonuria</title><author>Ford S,</author><journal>Mol Genet Metab Rep</journal><year>2018</year><book /><volume>17</volume><number>0</number><pages>64-68</pages><co_aut>ODriscoll M, MacDonald A</co_aut></literature><literature><id>6381</id><title>50 Years Ago in The Journal of Pediatrics: Maternal Phenylketonuria: Implications for Growth and Development</title><author>Ross LF,</author><journal>J Pediatr</journal><year>2018</year><book /><volume>201</volume><number>0</number><pages>121</pages><co_aut>Paul DB</co_aut></literature><literature><id>6383</id><title>50 Years Ago in The Journal of Pediatrics: Variability in the Manifestations of Phenylketonuria/Transient Hyperphenylalaninemia</title><author>Ross LF;</author><journal>J Pediatr</journal><year>2018</year><book /><volume>195</volume><number>0</number><pages>65</pages><co_aut>Paul DB</co_aut></literature><literature><id>6670</id><title>Unique aspects of sequence variant interpretation for inborn errors of metabolism (IEM): The ClinGen IEM Working Group and the </title><author>Zastrow DB,</author><journal>Hum Mutat</journal><year>2018</year><book /><volume>39</volume><number>11</number><pages>1569-1580</pages><co_aut>et al.</co_aut></literature><literature><id>6671</id><title>An overview of inborn errors of metabolism affecting the brain: from neurodevelopment to neurodegenerative disorders</title><author>Saudubray JM,</author><journal>Dialogues Clin Neurosci</journal><year>2018</year><book /><volume>20</volume><number>4</number><pages>301-325</pages><co_aut>Garcia-Cazorla A</co_aut></literature><literature><id>7200</id><title>Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria</title><author>Stroup BM,</author><journal>J Nutr</journal><year>2018</year><book /><volume>148</volume><number>2</number><pages>194-201</pages><co_aut>et al.</co_aut></literature><literature><id>3969</id><title>Key European guidelines for the diagnosis and management of patients with phenylketonuria</title><author>van Spronsen FJ,</author><journal>Lancet Diabetes Endocrinol</journal><year>2017</year><book /><volume>5</volume><number>9</number><pages>743-756</pages><co_aut>et al.</co_aut></literature><literature><id>4369</id><title>Altered tetrahydrobiopterin metabolism in patients with phenylalanine hydroxylase deficiency</title><author>Nardecchia F,</author><journal>Eur J Pediatr</journal><year>2017</year><book /><volume>176</volume><number>7</number><pages>917-924</pages><co_aut>et al.</co_aut></literature><literature><id>5154</id><title>Issues with European guidelines for phenylketonuria</title><author>Peter Burgard,</author><journal>Lancet Diabetes Endocrinol</journal><year>2017</year><book /><volume>5</volume><number>9</number><pages>681-683</pages><co_aut>et al.</co_aut></literature><literature><id>5208</id><title>When one disease is not enough: succinyl-CoA: 3-oxoacid coenzyme A transferase (SCOT) deficiency due to a novel mutation in OXC</title><author>Schwade JN,</author><journal>J Pediatr Endocrinol Metab</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>5681</id><title>Autism Spectrum Disorder and Phenylketonuria: Dyzygotic Twins with Double Syndrome</title><author>Demirci E</author><journal>Noro Psikiyatr Ars</journal><year>2017</year><book /><volume>54</volume><number>1</number><pages>92-93</pages><co_aut /></literature><literature><id>5860</id><title>Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study</title><author>Bilder DA,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>121</volume><number>1</number><pages>1-8</pages><co_aut>et al.</co_aut></literature><literature><id>5861</id><title>The Effects of Breastfeeding in Infants With Phenylketonuria</title><author>Kose E,</author><journal>J Pediatr Nurs. 2017 Oct 19;38:27-32</journal><year>2017</year><book /><volume>38</volume><number>0</number><pages>27-32</pages><co_aut>et al.</co_aut></literature><literature><id>5862</id><title>Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria</title><author>Boot E,</author><journal>Psychol Med</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages>1-12</pages><co_aut>et al.</co_aut></literature><literature><id>5863</id><title>Phenylalanine Hydroxylase Deficiency</title><author>Regier DS,</author><journal>GeneReviews&#174; [Internet]</journal><year>2017</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Greene CL</co_aut></literature><literature><id>3290</id><title>Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.</title><author>Gessler DJ,</author><journal>Methods Mol Biol</journal><year>2016</year><book /><volume>1382</volume><number>0</number><pages>429-465</pages><co_aut>Gao G</co_aut></literature><literature><id>3295</id><title>Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results</title><author>Gizewska M,</author><journal>Eur J Pediatr</journal><year>2016</year><book /><volume>175</volume><number>2</number><pages>261-272</pages><co_aut>et al.</co_aut></literature><literature><id>3970</id><title>Genetics of Phenylketonuria: Then and Now</title><author>Blau N</author><journal>Hum Mutat</journal><year>2016</year><book /><volume>37</volume><number>6</number><pages>508-515</pages><co_aut /></literature><literature><id>3971</id><title>Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach</title><author>Singh RH,</author><journal>Mol Genet Metab</journal><year>2016</year><book /><volume>118</volume><number>2</number><pages>72-83</pages><co_aut>et al.</co_aut></literature><literature><id>5682</id><title>Autism in Phenylketonuria Patients: From Clinical Presentation to Molecular Defects</title><author>Khemir S,</author><journal>J Child Neurol</journal><year>2016</year><book /><volume>31</volume><number>7</number><pages>843-849</pages><co_aut>et al.</co_aut></literature><literature><id>6883</id><title>The first Mongolian cases of phenylketonuria in selective screening of inborn errors of metabolism</title><author>Purevsuren J,</author><journal>Mol Genet Metab Rep</journal><year>2016</year><book /><volume>9</volume><number>0</number><pages>71-74</pages><co_aut>et al.</co_aut></literature><literature><id>3291</id><title>Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations</title><author>Schuck PF,</author><journal>Aging Dis</journal><year>2015</year><book /><volume>6</volume><number>5</number><pages>390-399</pages><co_aut>et al.</co_aut></literature><literature><id>3292</id><title>Protein substitute for children and adults with phenylketonuria</title><author>Yi SH,</author><journal>Cochrane Database Syst Rev</journal><year>2015</year><book /><volume>2</volume><number>0</number><pages /><co_aut>Singh RH</co_aut></literature><literature><id>3294</id><title>The challenges of managing coexistent disorders with phenylketonuria: 30 cases</title><author>MacDonald A,</author><journal>Mol Genet Metab</journal><year>2015</year><book /><volume>116</volume><number>40</number><pages>242-251</pages><co_aut>et al.</co_aut></literature><literature><id>3296</id><title>Management of adult patients with phenylketonuria: survey results from 24 countries</title><author>Trefz FK,</author><journal>Eur J Pediatr</journal><year>2015</year><book /><volume>174</volume><number>1</number><pages>119-127</pages><co_aut>et al.</co_aut></literature><literature><id>3293</id><title>New Strategies for the Treatment of Phenylketonuria (PKU)</title><author>Strisciuglio P,</author><journal>Metabolites</journal><year>2014</year><book /><volume>4</volume><number>4</number><pages>1007-1017</pages><co_aut>Concolino D</co_aut></literature><literature><id>3297</id><title>Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases</title><author>Feillet F,</author><journal>J Inherit Metab Dis</journal><year>2014</year><book /><volume>37</volume><number>5</number><pages>753-762</pages><co_aut>et al.</co_aut></literature><literature><id>3303</id><title>Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes</title><author>Cleary M,</author><journal>Mol Genet Metab</journal><year>2013</year><book /><volume>110</volume><number>4</number><pages>418-423</pages><co_aut>et al.</co_aut></literature><literature><id>3304</id><title>Is overweight an issue in phenylketonuria?</title><author>Rocha JC,</author><journal>Mol Genet Metab Suppl</journal><year>2013</year><book /><volume>110</volume><number>0</number><pages>S18-S24</pages><co_aut>MacDonald A, Trefz F</co_aut></literature><literature><id>3306</id><title>Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany</title><author>Lindner M,</author><journal>Orphanet J Rare Dis</journal><year>2011</year><book /><volume>6</volume><number>44</number><pages /><co_aut>et al.</co_aut></literature><literature><id>3307</id><title>Long-term follow-up of patients with phenylketonuria receiving tetrahydrobiopterin treatment</title><author>Trefz FK,</author><journal>J Inherit Metab Dis Suppl 3</journal><year>2010</year><book /><volume>0</volume><number>0</number><pages>S163-S169</pages><co_aut>Scheible D, Frauendienst-Egger G</co_aut></literature><literature><id>2776</id><title>MANAGEMENT OF PHENYLKETONURIA IN EUROPE: A REVIEW FROM 8 COUNTRIES</title><author>Blau N</author><journal>J Inherit Metab Dis Suppl</journal><year>2008</year><book /><volume>31</volume><number>0</number><pages>83</pages><co_aut>et al.</co_aut></literature><literature><id>2777</id><title>The truth of treating patients with phenylketonuria after childhood: The need for a new guideline</title><author>van Spronsen FJ</author><journal>J Inherit Metab Dis</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Burgard P</co_aut></literature><literature><id>2778</id><title>Stability of blood phenylalanine levels and IQ in children with phenylketonuria</title><author>Anastasoaie V</author><journal>Mol Genet Metab</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>2779</id><title>What we know that could influence future treatment of phenylketonuria</title><author>Sarkissian CN</author><journal>J Inherit Metab Dis</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages /><co_aut>G&#225;mez A, Scriver CR</co_aut></literature><literature><id>2780</id><title>Finding the fertile woman with phenylketonuria</title><author>Hanley WB.</author><journal>Eur J Obstet Gynecol Reprod Biol</journal><year>2008</year><book /><volume>137</volume><number>2</number><pages>131-135</pages><co_aut /></literature><literature><id>2782</id><title>SIGNIFICANCE OF GENOTYPE IN TETRABIOPTERIN (BH4)-RESPONSIVE PHENYLKETONURIA (PKU)</title><author>Trefz FK</author><journal>J Inherit Metab Dis Suppl 1</journal><year>2008</year><book /><volume>0</volume><number>0</number><pages>82</pages><co_aut>et al.</co_aut></literature><literature><id>2751</id><title>The tetrahydrobiopterin loading test in 36 patients with hyperphenylalaninaemia: evaluation of response and subsequent treatmen</title><author>Boveda MD</author><journal>J Inherit Metab Dis. 2007 Oct;30(5):812. Epub 2007 Jun 21</journal><year>2007</year><book /><volume>30</volume><number>5</number><pages>812</pages><co_aut>et al.</co_aut></literature><literature><id>2781</id><title>Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria</title><author>Burnett JR. </author><journal>IDrugs</journal><year>2007</year><book /><volume>10</volume><number>11</number><pages>805-813</pages><co_aut /></literature><literature><id>2610</id><title>Ready to drink protein substitute is easier is for people with phenylketonuria</title><author>Macdonald A</author><journal>J Inher Met Dis</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>526-531</pages><co_aut>et al.</co_aut></literature><literature><id>2621</id><title>Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU)</title><author>Hvas AM</author><journal>J Inher Met Dis</journal><year>2006</year><book /><volume>29</volume><number>0</number><pages>47-63</pages><co_aut>Nexo E, Nielsen JB</co_aut></literature><literature><id>2752</id><title>The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase defic</title><author>Leuzzi V</author><journal>J Inherit Metab Dis</journal><year>2006</year><book /><volume>29</volume><number>1</number><pages>38-46</pages><co_aut>et al.</co_aut></literature><literature><id>2753</id><title>[Tetrahydrobiopterin therapy for hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. When and how?]</title><author>Baldellou V+&#237;zquez A</author><journal>An Pediatr (Barc). 2006 Feb;64(2):146-52</journal><year>2006</year><book /><volume>64</volume><number>2</number><pages>146-152</pages><co_aut>et al.</co_aut></literature><literature><id>2372</id><title>Breastfeeding experience in inborn errors of metabolism other than phenylketonuria</title><author>Huner G</author><journal>J Inherit Metab Dis</journal><year>2005</year><book /><volume>28</volume><number>4</number><pages>457-465</pages><co_aut>et al.</co_aut></literature><literature><id>2568</id><title>Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin</title><author>Trefz FK</author><journal>Mol Genet Metab Suppl 1</journal><year>2005</year><book /><volume>86</volume><number>0</number><pages>S75-80</pages><co_aut>et al.</co_aut></literature><literature><id>2569</id><title>Response of patients with phenylketonuria in the US to tetrahydrobiopterin</title><author>Matalon R</author><journal>Mol Genet Metab Suppl 1</journal><year>2005</year><book /><volume>0</volume><number>0</number><pages>S17-S21</pages><co_aut>et al.</co_aut></literature><literature><id>2749</id><title>Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study</title><author>Fiege B</author><journal>Mol Genet Metab. 2005 Dec;86 Suppl 1:S91-5. Epub 2005 Nov 11</journal><year>2005</year><book /><volume>0</volume><number>0</number><pages>S91-S95</pages><co_aut>et al.</co_aut></literature><literature><id>2750</id><title>Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketon</title><author>Hennermann JB</author><journal>Mol Genet Metab Suppl 1</journal><year>2005</year><book /><volume>0</volume><number>0</number><pages>S86-S90</pages><co_aut>et al.</co_aut></literature><literature><id>1311</id><title>Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxyla</title><author>Shintaku H</author><journal>Pediatr Res</journal><year>2004</year><book /><volume>55</volume><number>3</number><pages>425-430</pages><co_aut>et al.</co_aut></literature><literature><id>1312</id><title>Biopterin responsive phenylalanine hydroxylase deficiency</title><author>Matalon R</author><journal>Genet Med</journal><year>2004</year><book /><volume>6</volume><number>1</number><pages>27-32</pages><co_aut>et al.</co_aut></literature><literature><id>2163</id><title>Adult phenylketonuria</title><author>Hanley WB</author><journal>Am J Med</journal><year>2004</year><book /><volume>117</volume><number>8</number><pages>590-595</pages><co_aut /></literature><literature><id>2164</id><title>Trends in enzyme therapy for phenylketonuria</title><author>Kim W</author><journal>Mol Ther</journal><year>2004</year><book /><volume>10</volume><number>2</number><pages>220-224</pages><co_aut>et al.</co_aut></literature><literature><id>2165</id><title>The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency</title><author>Blau N</author><journal>Mol Genet Metab</journal><year>2004</year><book /><volume>82</volume><number>2</number><pages>101-111</pages><co_aut>Erlandsen H</co_aut></literature><literature><id>2166</id><title>Tetrahydrobiopterin responsiveness in patients with phenylketonuria</title><author>Perez-Duenas B</author><journal>Clin Biochem</journal><year>2004</year><book /><volume>37</volume><number>12</number><pages>1083-1090</pages><co_aut>et al.</co_aut></literature><literature><id>2754</id><title>Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydro</title><author>Erlandsen H</author><journal>Proc Natl Acad Sci U S A</journal><year>2004</year><book /><volume>101</volume><number>48</number><pages>16903-8</pages><co_aut>et al.</co_aut></literature><literature><id>2755</id><title>Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genot</title><author>Desviat LR</author><journal>Mol Genet Metab</journal><year>2004</year><book /><volume>83</volume><number>0</number><pages>157-162</pages><co_aut>et al.</co_aut></literature><literature><id>1313</id><title>Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria</title><author>Trefz FK</author><journal>Pediatrics</journal><year>2003</year><book /><volume>112</volume><number>0</number><pages>1566-1569</pages><co_aut>Blau N</co_aut></literature><literature><id>2748</id><title>BH4-sensitive hyperphenylalaninemia: new case and review of literature</title><author>L&#252;cke T</author><journal>Pediatr Neurol. 2003 Mar;28(3):228-30</journal><year>2003</year><book /><volume>28</volume><number>3</number><pages>228-230</pages><co_aut>et al.</co_aut></literature><literature><id>2756</id><title>Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency</title><author>Lindner M</author><journal>Hum Mutat. 2003 Apr;21(4):400</journal><year>2003</year><book /><volume>21</volume><number>4</number><pages>400</pages><co_aut>et al.</co_aut></literature><literature><id>1310</id><title>Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria</title><author>Muntau AC</author><journal>N Engl J Med</journal><year>2002</year><book /><volume>347</volume><number>26</number><pages>2122-2132</pages><co_aut>et al.</co_aut></literature><literature><id>1314</id><title>High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988</title><author>Bernegger C</author><journal>Mol Genet Metab</journal><year>2002</year><book /><volume>77</volume><number>4</number><pages>304-313</pages><co_aut>Blau N</co_aut></literature><literature><id>2757</id><title>Partial and total Tetrahydrobiopterin-responsiveness in classical and mild phenylketonuria (PKU)</title><author>Hennermann JB</author><journal>J Inher Met Dis Suppl 1</journal><year>2002</year><book /><volume>25</volume><number>0</number><pages>S21</pages><co_aut>et al.</co_aut></literature><literature><id>7304</id><title>Clinical analysis of West syndrome associated with phenylketonuria</title><author>Zhongshu Z,</author><journal>Brain Dev</journal><year>2001</year><book /><volume>23</volume><number>7</number><pages>552-557</pages><co_aut>et al.</co_aut></literature><literature><id>1147</id><title>Final intelligence in late treated patients with phenylketonuria</title><author>Trefz FK</author><journal>Eur J Pediatr Suppl 2</journal><year>2000</year><book /><volume>159</volume><number>0</number><pages>145-148</pages><co_aut>Cipcic-Schmidt S, Koch R</co_aut></literature><literature><id>926</id><title>Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997</title><author>Burgard P</author><journal>Eur J Pediatr</journal><year>1999</year><book /><volume>158</volume><number>0</number><pages>46-54</pages><co_aut>et al.</co_aut></literature><literature><id>975</id><title>Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria o</title><author>Chace DH</author><journal>Clin Chem</journal><year>1998</year><book /><volume>44</volume><number>0</number><pages>2405-2409</pages><co_aut>et al.</co_aut></literature><literature><id>979</id><title>[Neonatal screening in Denmark. status and future perspectives]</title><author>Simonsen H</author><journal>Ugeskr Laeger</journal><year>1998</year><book /><volume>160</volume><number>40</number><pages>5777-5782</pages><co_aut>et al.</co_aut></literature><literature><id>365</id><title>International database of tetrahydrobiopterin deficiencies</title><author>Blau N</author><journal>J Inherit Metab Dis</journal><year>1996</year><book /><volume>19</volume><number>0</number><pages>8-14</pages><co_aut>Barnes I, Dhondt JL</co_aut></literature><literature><id>454</id><title>Factors affecting the variation in plasma phenylalanine in patiets with phenylketonuria on diet</title><author>MacDonald A</author><journal>Arch Dis Child</journal><year>1996</year><book /><volume>74</volume><number>5</number><pages>412-417</pages><co_aut>et al.</co_aut></literature><literature><id>544</id><title>PAH Mutation Analysis Consortium Database: a database for a disease-producing and other allelic variation at the human PAH locus</title><author>Hoang L</author><journal>Nucleic Acids Res</journal><year>1996</year><book /><volume>24</volume><number>1</number><pages>127-131</pages><co_aut>Byck S, Prevost L, Scriver CR</co_aut></literature><literature><id>1008</id><title>Hyperphenylalaninemia</title><author>Blau N</author><journal>in Blau N, Duran M, Blaskovics E (eds): in Physicians guide to the laboratory diagnosis of metabolic diseases; Chapman and Hall, London</journal><year>1996</year><book /><volume>0</volume><number>0</number><pages>65-78</pages><co_aut>Blaskovics ME</co_aut></literature><literature><id>113</id><title>The hyperphenylalaninemias</title><author>Scriver CR</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>1</volume><number>0</number><pages>1015-1075</pages><co_aut>et al.</co_aut></literature><literature><id>261</id><title>Whatever happended to PKU?</title><author>Scriver CR</author><journal>Clin Biochem</journal><year>1995</year><book /><volume>28</volume><number>2</number><pages>137-144</pages><co_aut /></literature><literature><id>6590</id><title>Phenylketonuria and its variants</title><author>Kaufman S</author><journal>Adv Hum Genet</journal><year>1983</year><book /><volume>13</volume><number>0</number><pages>217-297</pages><co_aut /></literature><literature><id>6591</id><title>Phenylketonuria and its variants</title><author>Kaufman S</author><journal>Ann Clin Lab Sci</journal><year>1977</year><book /><volume>7</volume><number>2</number><pages>178-185</pages><co_aut>Milstien S</co_aut></literature><literature><id>6592</id><title>Phenylketonuria: Biochemical Mechanisms</title><author>Kaufman S</author><journal>Advances in Neurochemistry</journal><year>1977</year><book /><volume>0</volume><number>0</number><pages /><co_aut /></literature></Literatures></Disease>